Veracyte to present first prospective data on hormone therapy biomarker

SAN FRANCISCO - Veracyte, Inc. (NASDAQ:VCYT), a $2.69 billion diagnostics company with impressive 19.91% revenue growth over the last twelve months, will present the first prospective validation data for a molecular signature predicting hormone therapy benefit in men with recurrent prostate cancer at the upcoming ASTRO 2025 conference, according to a company press release. According to InvestingPro data, the company maintains a robust 70.55% gross profit margin, reflecting its strong market position in precision diagnostics.

The findings, derived using Veracyte’s Decipher GRID research tool, will be among nine Decipher-focused abstracts presented at the American Society for Radiation Oncology annual meeting, scheduled for September 27 to October 1 at the Moscone Center in San Francisco. The company’s strong financial position, with more cash than debt on its balance sheet and a healthy current ratio of 5.43, supports its continued investment in research and development.

Six of the abstracts have been selected for podium presentations, including a double-blinded placebo-controlled biomarker stratified randomized trial of apalutamide and radiotherapy for recurrent prostate cancer, presented by Dr. Daniel Spratt of University Hospitals Seidman Cancer Center on September 28.

Another key presentation will address the discordance of adverse molecular features between genomic classifier scores, histologic grade, and NCCN risk groups, analyzing data from over 200,000 patients.

"Such insights will ultimately make prostate cancer care more precise, giving greater molecular dimension to the classification and treatment of the disease," said Elai Davicioni, Veracyte’s medical director for Urology, in the press release.

The Decipher GRID database includes more than 200,000 whole-transcriptome profiles from patients with urologic cancers. The company’s Decipher Prostate Genomic Classifier is a 22-gene test that helps inform treatment decisions for patients across the spectrum of prostate cancer.

The test has been demonstrated in over 90 studies involving more than 200,000 patients and is the only gene expression test to achieve Level I evidence status in the NCCN Guidelines for prostate cancer, according to the company.

In other recent news, Veracyte Inc. reported impressive second-quarter 2025 earnings, with earnings per share of $0.44, significantly surpassing the forecast of $0.11. The company also reported revenue of $130.2 million, exceeding the expected $121.1 million. Despite these strong financial results, Morgan Stanley lowered its price target for Veracyte from $29 to $28, maintaining an Underweight rating, while noting a "solid 2Q beat" driven by the Decipher and Afirma product lines. In contrast, William Blair reiterated an Outperform rating for Veracyte following its strong second-quarter performance, which exceeded analyst expectations with revenue 8% ahead of consensus estimates. Additionally, Veracyte announced the completion of patient enrollment for its NIGHTINGALE clinical trial, which aims to evaluate the effectiveness of the Percepta Nasal Swab test for lung nodule assessment. The trial involves 2,400 patients across over 90 centers in the United States and will determine if the test reduces unnecessary procedures for benign nodules. These developments highlight Veracyte’s ongoing progress and activities in the diagnostic field.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.